Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409262 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 649
- Enrollment target
NCT04409262: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT04409262 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 649 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04409262, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 649 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
Primary Outcome
Defined as days from randomization to hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. Hospital discharge or "Ready for Discharge" is defined as an ordinal score of 1 on the 7-point ordinal scale. Participants who die are censored at Day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensi
Interventions
- DRUG Placebo
- DRUG Tocilizumab
- DRUG Remdesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 649 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 3 |
What the finished NCT04409262 record still lists
NCT04409262 is an interventional study that assigns participants to a tested intervention. The registered 649 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04409262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04409262 about?
NCT04409262 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia". This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
What is the current status of trial NCT04409262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 649 participants. The study started on 2020-06-16. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT04409262?
The interventions under investigation include: Placebo (DRUG), Tocilizumab (DRUG), Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04409262?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04409262's enrollment target sits among peer trials
649 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI